open access
Short-acting inhaled β2-agonists: why, whom, what, how?
Affiliations- Klinika Chorób Płuc i Reumatologii Dziecięcej, Uniwersytet Medyczny w Lublinie
- Katedra i Zakład Pielęgniarstwa Internistycznego, Uniwersytet Medyczny w Lublinie
open access
Abstract
We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.
Abstract
We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.
Keywords
short-acting β2-agonist; salbutamol; fenoterol; inhalation; nebulization; asthma; COPD
About this articleTitle
Short-acting inhaled β2-agonists: why, whom, what, how?
Journal
Advances in Respiratory Medicine
Issue
Article type
Review paper
Pages
443-449
Published online
2020-10-30
DOI
10.5603/ARM.a2020.0132
Pubmed
Bibliographic record
Adv Respir Med 2020;88(5):443-449.
Keywords
short-acting β2-agonist
salbutamol
fenoterol
inhalation
nebulization
asthma
COPD
Authors
Andrzej Emeryk
Justyna Emeryk-Maksymiuk